{"nctId":"NCT04147650","briefTitle":"Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome","startDateStruct":{"date":"2019-10-14","type":"ACTUAL"},"conditions":["Dry Eye Syndrome","Keratoconjunctivitis Sicca"],"count":508,"armGroups":[{"label":"0.05% Voclosporin Ophthalmic Solution (VOS)","type":"EXPERIMENTAL","interventionNames":["Drug: 0.05% Voclosporin Ophthalmic Solution (VOS)"]},{"label":"0.10% VOS","type":"EXPERIMENTAL","interventionNames":["Drug: 0.10% VOS"]},{"label":"0.20% VOS","type":"EXPERIMENTAL","interventionNames":["Drug: 0.20% VOS"]},{"label":"Vehicle Ophthalmic Solution","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle Ophthalmic Solution"]}],"interventions":[{"name":"0.05% Voclosporin Ophthalmic Solution (VOS)","otherNames":[]},{"name":"0.10% VOS","otherNames":[]},{"name":"0.20% VOS","otherNames":[]},{"name":"Vehicle Ophthalmic Solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be at least 18 years of age.\n* Have a documented history of Dry Eye prior to Visit 1.\n* Willing and able to follow protocol procedures and instructions.\n\nExclusion criteria:\n\n* Have undergone cataract or LASIK surgery within 1 year prior to Visit 1.\n* Recent or current evidence of infection or inflammation in either eye.\n* Current evidence of blepharitis, other meibomian gland dysfunction, conjunctivitis or history of herpes simplex or zoster keratitis in either eye.\n* Have used any investigational drug or device within 30 days prior to Visit 1.\n* Have used ophthalmic drugs (any topical eye medications) including prescription medication and over the counter (OTC) agents on the date of Visit 1.\n* Have worn contact lenses 24 hours prior to Visit 1.\n* Have used Xiidra® (lifitegrast) within 14 days prior to Visit 1.\n* Have used Calcineurin Inhibitors (CNIs) such as Restasis® (cyclosporin ophthalmic emulsion) or CequaTM within 30 days prior to Visit 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With a ≥10 mm Increase From Baseline in Schirmer Tear Test (STT)","description":"Number of subjects with a ≥10 mm increase from baseline in STT at Week 4 in the study eye. The STT scale is a measure of tear production with a minimum of 0 mm and no there is no specified maximum for this scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eye Dryness","description":"Mean change from baseline in Eye Dryness Visual Analogue Scale (VAS) in subjects with a baseline Eye Dryness VAS score ≥ 60 mm. Eye Dryness Visual Analogue Scale 0-100 mm, where 0 corresponds to \"no discomfort\" and 100 corresponds to \"maximal discomfort.\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"21.80"},{"groupId":"OG001","value":"-9.3","spread":"20.00"},{"groupId":"OG002","value":"-5.0","spread":"17.68"},{"groupId":"OG003","value":"-7.0","spread":"17.59"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":127},"commonTop":["Instillation site pain"]}}}